Objective
Adenosine deaminase acting on RNA-1 (ADAR1) enzyme is a type I interferon (IFN)-stimulated gene (ISG) catalyzing the deamination of adenosine-to-inosine, a process called A-to-I RNA editing. A-to-I RNA editing takes place mainly in
Alu
elements comprising a primate-specific level of post-transcriptional gene regulation. Whether RNA editing is involved in type I IFN responses in systemic sclerosis (SSc) patients remains unknown.
Methods
ISG expression was quantified in skin biopsies and peripheral blood mononuclear cells derived from SSc patients and healthy subjects. A-to-I RNA editing was examined in the ADAR1-target cathepsin S (
CTSS
) by an RNA editing assay. The effect of ADAR1 on interferon-α/β-induced
CTSS
expression was assessed in human endothelial cells
in vitro
.
Results
Increased expression levels of the RNA editor
ADAR1
, and specifically the long ADAR1p150 isoform, and its target
CTSS
are strongly associated with type I IFN signature in skin biopsies and peripheral blood derived from SSc patients. Notably, IFN-α/β-treated human endothelial cells show 8-10-fold increased ADAR1p150 and 23-35-fold increased
CTSS
expression, while silencing of ADAR1 reduces
CTSS
expression by 60-70%. In SSc patients, increased RNA editing rate of individual adenosines located in CTSS 3
′
UTR
Alu
elements is associated with higher
CTSS
expression (r = 0.36–0.6, P < 0.05 for all). Similar findings were obtained in subjects with activated type I IFN responses including SLE patients or healthy subjects after influenza vaccination.
Conclusion
ADAR1p150-mediated A-to-I RNA editing is critically involved in type I IFN responses highlighting the importance of post-transcriptional regulation of proinflammatory gene expression in systemic autoimmunity, including SSc.